Sight Sciences Drops in Pre-Market Trade as Investors Watch SGHT Growth
Sight Sciences closed Wednesday at $4.87, down 2.4%, and was unchanged in premarket trading Thursday. The company raised its 2026 revenue guidance to $83–89 million after Q1 revenue rose 13% to $19.7 million. Investors are watching OMNI glaucoma demand, TearCare reimbursement, and the Alcon patent appeal. Market cap stands near $265 million.